Phase III Menveo Beats Menactra In Teen Meningitis
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis will submit vaccine for U.S. and overseas approval later this year.
You may also be interested in...
Novartis Vaccines Unit Makes Move Into Crowded CMV Competition
Licensing deal for AlphaVax’s Phase I CMV candidate also includes options for RSV vaccine candidate and 4 million share stock purchase.
Novartis Vaccines Unit Makes Move Into Crowded CMV Competition
Licensing deal for AlphaVax’s Phase I CMV candidate also includes options for RSV vaccine candidate and 4 million share stock purchase.
Novartis Meningitis Blockbuster Strategy Key To Firm’s Vaccine Growth
Novartis plans to submit ACWY meningitis BLA in the second half, putting Menveo on track for approval in 2009.